initi buy oral phase cancer drug
w/ high probabl success
initi buy pt base oral taxan drug tesetaxel enrol
phase high probabl hit primari endpoint new
indic like start ad opportun
potenti chemo-combo potenti collaboration/d
repres attract late-stag phase cancer play primari valu
driver tesetaxel oral taxan pill creat signific valu time
upsid scenario base phase breast cancer studi read
probabl success cours similar oral late-stag cancer compani
would high probabl scenario given drug would easili fit
synergist mani big pharma/biotech cancer portfolio see attract valu
proposit across mani indic simpl oral cancer pill elimin key issu
current iv taxan inconveni poor side effects/toler etc management also
long histori prior invest success
question insid address key debat although phase
data long-term investor reward phase line breast
cancer studi work big catalyst pt dose
tesetaxel clear efficaci across tumor type includ orr respons
breast cancer similar taxan on-target side effect neutropenia seen
actual de-risk efficaci prove activ drug simpl
chemo regimen vs drug design tesetaxel cape vs cape alon prior phase studi
breast cancer show clearli work prior registr studi taxotere/
cape vs taxoter alon also think work pot collabor
better chemo-combo given success
although bear case lack near-term catalyst natur skeptic oral taxan
work competit histori develop daiichi genta prior clinic hold
believ dilig provid clear pictur explan see discuss insid
opportun hiccup daiichi/genta allow rapid develop odon
strong balanc sheet set path success develop
jefferi act joint book-run manag recent ipo
pt base probabl adjust dcf risk includ efficaci competit
gener estim cash debt balanc
quarterli ep estim jefco estim
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
base case base probability-
adjust dcf analysi odt lead program
current evalu tesetaxel metastat breast
assum probabl success
phase contessa studi believ
appropri given tesetaxel
somewhat de-risk previous conduct studi
first-lin mixed-lin mbc
compar iv taxan oral tesetaxel prior studi
shown compar efficaci plu better
upsid scenario assum higher
probabl success odt tesetaxel program
attribut probabl success
favor phase data readout would render
attract target given oral
tesetaxel would fit synergist novel drug
develop cancer portfolio big pharma/biotech
upsid scenario also assum small probabl
success import tumor type larg
market opportun could start
get ascrib valu time
downsid scenario assum cash
base potenti safeti issu aris
inabl tesetaxel meet phase primari
although downsid scenario assum
phase studi mbc contessa work
consid possibl advanc
tesetaxel indic gastric cancer
would repres upsid
believ repres attract long-
think primari valu driver tesetaxel oral taxan
pill creat signific value-cr time
upsid scenario base
phase breast cancer studi read
similar oral late-stag cancer compani think
would high probabl scenario
work given drug would easili fit synergist
mani big pharma/biotech cancer portfolio
simpl oral cancer pill elimin key issu
current
earli begin enrol phase patient local
potenti in-licens new compound
estim enrol complet phase
estim futil analysi dsmb
top-lin result phase studi patient
page
pleas see import disclosur inform page report
tabl content
question debat
rational contessa studi design
first-lin mbc phase ii tesetaxel monotherapi data chemo mbc patient
show orr month
mixed-lin mbc studi phase ii tesetaxel monotherapi data chemo
show notabl activ taxane-resist tumor
tesetaxel low-dos capecitabin solid tumor
tesetaxel monotherapi salvag set mbc
tesetaxel monotherapi cancer type
mechan action
tesetaxel market model suggest ww sale
histor project incom statement
histor project balanc sheet
histor project
page
pleas see import disclosur inform page report
initi buy pt base oral taxan drug tesetaxel
current enrol phase high probabl hit
primari endpoint like new indic start add
opportun potenti combin chemo-combo
collaboration/d could happen
believ repres attract long-term late-stag phase
cancer play think primari valu driver tesetaxel oral taxan pill
creat signific value-cr time
upsid scenario base phase breast cancer studi read
reason high probabl success cours similar
oral late-stag cancer compani think would high probabl
 scenario work given drug would easili fit synergist
mani big pharma/biotech cancer portfolio see attract
valu proposit across mani indic simpl oral cancer pill
elimin key issu current iv taxan inconveni poor side
although phase data bit far think long-term
investor reward phase line breast cancer studi
work show benefit least add month
month combin vs month monotherapi control think
data readout repres key catalyst pt
dose tesetaxel clear efficaci across tumor type
includ orr respons breast cancer similar
taxan on-target side effect neutropenia seen actual de-
risk efficaci prove activ drug simpl chemo
regimen vs drug design tesetaxel cape vs cape alon prior phase
studi breast cancer show clearli work prior
registr studi taxotere/cap vs taxoter alon
overal think tesetaxel sever key differ convent
iv taxan novel oral taxan develop oral administr
rout via pill provid patient conveni better toler
less seriou neuropathi much less alopecia hair loss
competitor daehwa use dose
drug tradit weekli iv
bear case lack near-term catalyst natur skeptic
oral taxan work competit histori develop daiichi
genta prior clinic hold howev dilig provid clear pictur
explan opportun aris hiccup genta allow
straight-forward develop odon well-financ balanc
sheet set path success develop
believ oral taxan drug import benefit patient
still requir chemotherapi standard care breast cancer
patient meant pretend new riski
immunotherapi i/o regimen realiti potent cytotox drug like
chemotherapi still mainstay treatment proven chemo-combo
still suggest chemo may import futur regimen
even around clear efficaci de-risk
page
pleas see import disclosur inform page report
concern late-stag i/o differ cancer drug inde
investor may skeptic oral taxan believ drug
repres signific innov breakthrough would note
drug test patient daiichi clinic hold due
death neutropenia yet patient primarili differ tumor
type gastric breast cancer pt fail get standard
treat neutropenia genta in-licens upon
analysi fda remov clinic hold genta treat pt
genta unfortun financi issu relat total separ
drug tesetaxel get capit need advanc phase
drug capit via odon odon buy-in
fda run phase combo tesetaxel/xeloda vs xeloda
alon vs one drug prior chemo regimen suggest clear ad
efficacy/synergi rais probabl success contessa phase
page
pleas see import disclosur inform page report
base case base probability-adjust dcf analysi odt lead
program current evalu tesetaxel metastat breast cancer mbc
patient assum probabl success phase contessa studi
believ appropri given tesetaxel somewhat de-risk
previous conduct studi first-lin mixed-lin mbc compar iv
taxan oral tesetaxel prior studi shown compar efficaci plu
upsid scenario assum higher probabl success odt tesetaxel
program attribut probabl success phase studi upsid
scenario assum favor phase data readout would render
attract target given oral tesetaxel would fit synergist novel drug
develop within cancer portfolio big pharma/biotech upsid scenario also
assum small probabl success import tumor type larg market
opportun could start get ascrib valu time
downsid scenario assum cash base potenti safeti issu
aris inabl tesetaxel meet phase primari endpoint although
downsid scenario assum phase studi mbc contessa play
expect consid possibl advanc tesetaxel
indic gastric cancer would repres upsid
page
pleas see import disclosur inform page report
tesetaxel phase trial contessa face delay fail meet
primari endpoint clinic trial risk could includ implement anoth
clinic hold due emerg safeti advers event clinic manufactur drug
product delay enrol delay caus increas expenditur chang
regulatori requir caus make amend protocol failur
demonstr efficaci benefit past preclinical/clin studi may indic
studi result
safeti risk tesetaxel could gener unfavor side effect properti delay
prevent approv limit commerci opportun result unfavor outcom
commerci price risk even tesetaxel receiv regulatori approv
commerci adopt could limit accept third-parti payor physician
patient physician patient may unwil prescrib tri new therapi
like tesetaxel due drug anticip higher price point vs gener
patent risk own issu patent exclus licens
daiichi composit matter com patent expir latter
salt crystal formul wherea total five eu japanes com patent expir
latest us would need request patent term restor
hatch-waxman extend protect salt crystal patent year
ou may need reli regulatori exclus eu
japan supplementari protect certif protect tesetaxel around
advantag compani develop novel oral taxan
believ candid could come ahead face clinic regulatori setback
tesetaxel addit mani competitor greater financi technic
resourc other may secur strateg partnership fund
may becom unsuccess licens acquir product
candid odt long-term strategi becom best-in-class cancer compani
pursu therapeut address variou cancer could includ ovarian lung
gastric solid tumor effort identifi acquir addit product
candid could play unfavor even success in-licens
product candid develop activ could requir substanti resourc
even fail achiev regulatori approv
page
pleas see import disclosur inform page report
question debat
convent taxan chemotherapi
intraven iv administ taxan mainstay modern
chemo treatment metastat breast cancer use limit
gener toxic advers event infusion-rel
hypersensit sometim fatal requir pre-treat antihistamin
corticosteroid demand extend patient monitor healthcar
personnel grade neuropathi acquir drug resist
tesetaxel offer sever advantag iv taxan list order
import
tesetaxel oral pill taken everi three week home enabl
patient avoid infus center versu standard care like paclitaxel
abraxan requir weekli iv infus center also unlik iv taxan
tesetaxel conveni combin oral capecitabin
enhanc efficaci help patient delay inevit need visit infus center
tesetaxel efficaci orr gener compar potent
taxan nuanc tesetaxel show potent antitumor activ taxane-
resist patient high p-gp express level preclin
clinic studi tesetaxel cell-kil potenc agnost p-gp express level
instanc grade peripher neuropathi mbc tesetaxel
dose compar docetaxel paclitaxel
addit grade alopecia hair loss much less frequent tesetaxel physician
patient tend weigh two symptom gr neuropathi plu gr alopecia
choos chemo regimen separ tesetaxel associ
allerg reaction circumv tradit requisit pre-med
oral taxan mbc tesetaxel differenti
oraxol compani orascoveri platform base small
molecul p-gp pump blocker facil oral absorpt
tradit cytotox enabl administ oral formul
paclitaxel oraxol docetaxel oradoxel high-dos instanc
oraxol paclitaxel pass first interim analysi
patient phase mbc studi septemb expect
second interim analysi posit could prompt fda
permit file nda base phase studi
specif toward p-gp mean less interfer activ
relat transport decreas inhibit cytochrom
enzym metabol commonli use drug minim
absorb gut limit potenti interact
compound system site p-gp express
howev would note atnx oraxol program aim improv
taxan molecul instead leverag p-gp pump blocker facilit
page
pleas see import disclosur inform page report
larg amount taxan dose therebi increas bioavail view
design much like pi proteas inhibitor booster like cobicistat ritonavir hiv
contrast tesetaxel novel compound modifi taxan structur
turn enabl drug circumv need booster allow
significantli less pill burden patient
forese regulatori risk type drug design given p-
gp blocker caus contraind alter blood level cancer
patient typic take variou medic one time believ
would need gener consider amount safeti data demonstr
patient take safe
administr oraxol paclitaxel also inconveni
take p-gp blocker patient must wait hour take
paclitaxel capsul regulatori preced take drug first
wait hour take drug hiv cobicistat ritonavir
co-formul singl pill mitig type confus risk
addit use signific amount taxan capsul around
capsul day atnx phase mbc studi oraxol
paclitaxel plu given consecut day week
week oraxol suppli capsul
atnx phase mbc studi control arm use standard regimen
control arm evalu paclitaxel everi three week instead
approv dose frequenc everi week qw studi shown qw
paclitaxel show superior efficaci paclitaxel comparison
keenli design control arm phase studi contessa use
capecitabin approv dose dose schedul
daehwa pharmaceut daehwa develop novel oral
paclitaxel formul call treatment breast stomach
cancer latter approv sep korea liporaxel daehwa
current run phase ii us-bas studi recurrent/metastat breast
accord daehwa presid han-koo compani work oral
paclitaxel formul sinc daehwa goal elimin need
cancer patient spend hour wait receiv iv chemo hospit mr koo
believ approv oral chemo drug enabl cancer patient stay
home visit hospit time prescript refil daehwa
design dissolv water absorb edibl oil
contain nontox substanc absorpt rate
liporaxel approv korea drinkabl liquid gastric
patient take daili via two bottl believ similar oraxol
drug use consider high dose iv paclitaxel hope allow
gi tract absorb fraction dose also korean liporaxel label note
drug caus signific nausea vomit
safeti risk stori behind tesetaxel clinic
hold wont safeti issu aris phase
fda place clinic hold tesetaxel drug clinic
studi conduct daiichi hold driven case sever neutropenia
low white blood count led cluster seven death patient
page
pleas see import disclosur inform page report
die suffer gastric cancer consid late-stag patient
receiv sever prior line chemotherapi compar mbc gastric
cancer patient tend prone infect sinc gastric cancer
popul hole stomach drive sepsi risk would note
neutropenia case expect lower breast cancer
convent practic treat neutropenia neulasta
howev tesetaxel patient die receiv
genta licens tesetaxel daiichi march tesetaxel still
clinic hold howev genta understood on-going issu program
well develop plan safeguard neutropenia neupogen
administr compani file respons fda request
lift hold fda later grant june genta sinc treat
hold fda
retrospect believ observ instanc neutropenia differ
seen chemo agent specif phase ii tesetaxel monotherapi
studi mbc patient show patient grade
neutropenia tesetaxel studi show high end
rang would note rate grade neutropenia
tesetaxel consist seen docetaxel paclitaxel abraxan
base literatur
tesetaxel show win bar approv
initi phase studi mbc cancer patient contessa
expect complet enrol around report top-lin result
evalu mbc patient hr-posit
status previous treat taxan neoadjuv prior
surgeri adjuv immedi follow surgeri
studi design tesetaxel day cycl low-dos
capecitabin bid day cycl versu capecitabin
bid day cycl
kol suggest phase hurdl tesetaxel low-dos
signific extend
progress free surviv month month expect
capecitabin month sever clinic studi provid
evid afford lower capecitabin dose
approv dose hope reduc drug known side effect grade
hand-foot syndrom hf diarrhea without jeopard efficaci fact
ad low-dos cape tesetaxel actual improv overal efficaci
benefit sinc patient would theoret stay longer drug
idea test low-dos capecitabin support notabl
studi oshaughnessi cape doci low dose
compar doci high dose studi compar arm high dose
doci saw dose reduct rate patient would drop
otherwis versu activ arm cape low-dos doci
would also expect see greater rate toxic control arm make
page
pleas see import disclosur inform page report
recent drug approv mbc also provid favor preced cape
approv base cape doci vs doci alon oshaughnessi studi
gemcitabin gemzar approv base gem pac vs pac alon ibranc
approv base ibranc letrozol vs letrozol alon paloma studi
pipelin investor buy stock
tesetaxel data
compani prefer specul possibl believ
thoroughli evalu tesetaxel opportun
consid initi new clinic studi differ tumor type add
potenti commerci opportun could see announc
follow-on plan tesetaxel given convent taxan abraxan
three five approv indic believ indic expans gastric
cancer would make rational sens given single-ag tesetaxel
believ anoth avenu explor could entail tesetaxel
combo program sinc taxan provid great backbon cancer
treatment fact concept somewhat de-risk celg work
roch develop abraxan atezolizumab chemo combo nsclc
impow tnbc impass dataset program
expect believ posit dataset celg/roch would
make inclin pursu avenu
also believ like in-licens new asset
broaden pipelin believ compani could look novel asset
ovarian lung adjuv breast cancer tang capit primari investor
evalu addit busi opportun busi develop bd activ
relat cancer shuttl compani develop
page
pleas see import disclosur inform page report
compani late-stag phase asset yet trade inexpens rel
tesetaxel dataset fairli robust treat patient studi
oral taxan shown compar efficaci lower toxic toler
tesetaxel efficaci profil mbc somewhat de-risk previous conduct
studi mixed-lin mbc show orr
number key opinion leader breast cancer joyc oshaughnessi denis
yardley andrew seidmar etc awar tesetaxel drug valid
doctor activ help publish complet studi journal
present offici medic confer
tesetaxel shown strong activ taxane-resist patient preclin
chemo-resist cell line clinic set studi mixed-lin mbc
patient activ high p-gp express taxan resist someth iv
taxan achiev
contessa two cytotox tese cape complementari mechan
low-dos cape show synerg minim incid toxic
contessa keenli select approv dose capecitabin
control oppos use approv taxan like paclitaxel oral cape
perceiv less efficaci iv taxan
contessa ad low-dos cape actual improv efficaci sinc patient
stay drug longer patient tend dose reduc cape anyway due grade
recent drug approv mbc provid favor preced cape
approv base cape low-dos doci vs doci alon oshaughnessi studi
gemcitabin gemzar approv base gem pac vs pac alon
ibranc approv base ibranc letrozol vs letrozol alon paloma
studi rel context odt phase contessa studi evalu
cancer patient strong prefer oral drug versu iv oral xeloda
capecitabin gener peak ww sale go gener
ibranc claim fame oral pill even though ibranc high price
drug sell appeal patient
abraxan sale trend ww annual despit face reimburs
pushback drug iv definit market tesetaxel
annual drug price ibranc abraxan tesetaxel
anticip annual price point would seem reason appeal
tesetaxel shown compel activ orr gastric cancer
provid opportun expand tesetaxel label futur
compani in-licens cancer asset start combo
data investor stock
tesetaxel previous place clinic hold fda
competitor develop novel paclitaxel formul late-stag studi
well alreadi drug approv asian market need
run bioequival studi fda sign type strategi alreadi
page
pleas see import disclosur inform page report
daiichi ran sever tesetaxel studi daiichi out-licens
drug genta begin
genta didnt consid mbc tesetaxel lead incit instead genta
pursu gastric cancer pursu mbc gastric
sound good true tesetaxel show significantli lower side effect
daiichi/genta manag avoid safeti issu seen paclitaxel
drug sit shelf long becom relev
sinc found taken long start phase
drug compel wasnt sold celg big specialti pharma
dont larg compani show interest asset
need oral taxan paclitaxel gener abraxan go gener soon
would payor even pay post gener world
tesetaxel matter go domin i/o combo
differ chemo craze right
mbc chemo market crowd sever drug approv alreadi includ
taxan perceiv physician efficaci enough addit
athenex oraxol phase daehwa start phase ii studi us
nantpharma cynviloq -gen abraxan nda-readi sun pharma
taclanti pivot bioequival data
tesetaxel ip look weak compani may need find partner sell drug
page
pleas see import disclosur inform page report
chart valuat compar compani
page
pleas see import disclosur inform page report
companytickerratingpric targetpricelead drugdrug lead indicationstagemarket cap debt enterpris valu zejula niraparib ovarian puma neratinibbreast rubracaovarian cancer blueprint avapritnibgist smphase halozym cancerphas loxo trk fusionsphas array binimetinib cancer braf oraxolmbcphas mbc tesetaxelmbcphas prime cabiralizumab tumor pvn pancreaticphas newlink genet indoximod inhibitor advanc melanomaphas estim cash debt balanc post ipopr
found march led ceo kevin tang san diego-bas
cancer compani focus initi develop lead drug tesetaxel
oral chemotherapi agent belong taxan class wide use
cancer treatment rel intraven iv chemo regimen oral tesetaxel deliv
similar efficaci profil along better safety/toler particularli reduc case
hair loss elimin instanc peripher neuropathi hand-foot syndrom
diarrhea follow posit result two prior phase ii studi single-ag
tesetaxel well toler exhibit antitumor activ metastat breast cancer
mbc patient start phase mbc studi contessa
enrol complet expect top-lin result expect
decemb sold share price initi
public offer rais gross proce jefferi act joint book-
run manag offer estim net proce
plan use follow
conduct odt multi-national multicent phase contessa studi
mbc patient initi
launch clinic studi tesetaxel
fund manufactur activ relat tesetaxel
remain work capit gener corpor purpos
page
pleas see import disclosur inform page report
timeexpect newsflowprogramindicationearli enrol phase patient local advanc mbc in-licens compound cancer enrol complet phase contessa futil analysi dsmb result phase studi patient local advanc mbc contessa tesetaxelmbcprogramstageindicationmilestonetesetaxelphas metastat breast cancer mbc announc phase top-lin result
intraven iv administ taxan mainstay modern
chemotherapi metastat breast cancer use limit
toxic advers event infusion-rel hypersensit sometim
fatal requir pre-treat antihistamin corticosteroid demand
extend patient monitor healthcar personnel grade neuropathi
tesetaxel advantag oral administr allow low
pill burden enabl patient-friendli dose regimen non-solubl
formul castor oil otherwis
taxan
formul known caus allerg reaction hypersensit show
potent antitumor activ low-dos monotherapi combin
oral regimen capecitabin creat all-or rout enhanc
overal efficaci delay need patient receiv iv chemo infus center
contain
major breast cancer patient prefer oral therapi
sever breast cancer studi suggest breast cancer patient prefer oral
activ treatment rel good toler oral therapi
tesetaxel delay need receiv intraven chemo infus center
take sever hour complet addit market share oral therapi
increas sinc earli suggest strong prefer
oral drug offer low pill burden
chart studi breast cancer patient prefer oral versu iv therapi
single-ag tesetaxel beat iv taxan paclitaxel safeti
combin oral capecitabin boost efficaci
oral taxan tesetaxel aim elimin infus reaction associ
intraven taxan paclitaxel docetaxel maintain high anti-
tumor activ base preclin clinic data tesetaxel key safeti
benefit iv taxan includ
obviat risk taxane-rel hypersensit reaction
fatal tesetaxel formul free solubil agent found convent
elimin requir premed steroid anthihistamin
reduc peripher neuropathi damag peripher nerv
cross resist standard taxan
addit use oral rout enabl develop schedul
expand tesetaxel dose option combin tesetaxel
oral anti-cancer drug like capecitabin oral nucleosid metabol inhibitor
capecitabin xeloda commonli use treatment breast colon colorect
cancer approv dose day patient unabl
sustain treatment dose due develop hand-foot syndrom hf
page
pleas see import disclosur inform page report
studypublicationnpref oral prefer ivindifferentbeusterien oncologist preferred-ishitobi prefer adher cancer journal cancer
chart single-ag tesetaxel antitumor activ compar
paclitaxel capecitabin breast cancer
chart tesetaxel dose offer enhanc safeti profil rel
paclitaxel capecitabin breast cancer
cycl patient given tesetaxel everi day
intend dose averag bodi surfac area bsa adult
femal male averag bsa adult cancer patient
accord uk retrospect studi cancer patient given
tesetaxel capsul weigh data point would suggest tesetaxel
dose schedul conveni around pill per cycl
page
pleas see import disclosur inform page report
studi treat drug orr ttp/ tff month includ non-dos escal dose-escal cohort seidman et al random multicent studi first-lin chemotherapi treatment albainet al journal clinic oncolog bishop et al journal clinic oncolog gradishar et al european journal cancer gradisharet al journal clinic oncolog gray et al journal clinic oncolog paridaenset al journal clinic oncolog baselgaet al journal clinic oncolog harbecket al breast cancer treat goldstein et al annual meet oral present vahdatet al cancer earch oshaughnessi et al annal oncolog robert et al journal clinic oncolog stockleret al journal clinic oncolog twelv et al breast cancer neuropathi grade numb pain grade hair reportedhand-foot syndrom grade swell pain grade studi hf intern report treatment-rel patient random multicent studi first-lin chemotherapi treatment albain et al journal clinic oncolog bishop et al journal clinic oncolog gradishar et al european journal cancer gray et al journal clinic oncolog paridaen et al journal clinic oncolog harbecket al breast cancer treat oshaughnessi et al annal oncolog robert et al journal clinic oncolog stockler et al journal clinic oncolog
chart dose schedul paclitaxel capecitabin tesetaxel
page
pleas see import disclosur inform page report
paclitaxelcapecitabinetesetaxelrouteintravenousoraloralanti-allergi premedicationyesnonodos per dose pill per day experienceneedl sever hour pill per cyclefrequ
phase tesetaxel studi contessa
chemo patient mbc
initi phase studi mbc cancer patient contessa
expect report top-lin result random
multicent random open label studi evalu tesetaxel low-dos cape vs
cape alon mbc patient hr-posit status
previous treat taxan neoadjuv prior surgeri adjuv
immedi follow surgeri set addit plan submit clinic trial
applic ex-u countri compani plan recruit patient
random hr-posit mbc patient across
select inclus criteria patient must receiv one
chemotherapi regimen advanc diseas receiv taxan
neoadjuvant/adjuv set indic patient must receiv
anthracyclin endocrin therapi /- inhibitor limit
dose tesetaxel day cycl low-dos capecitabin
bid day cycl versu capecitabin bid
day cycl
primari endpoint progress free surviv design statist
power detect improv hazard ratio median
expect efficaci data readout earli compani expect
contessa take year fulli enrol around anoth year
report top-lin result
interim analys compani expect conduct safeti interim analys
period singl futil analysi one-third way studi
dsmb expect look result determin futil contessa
 whether studi doesnt effect
page
pleas see import disclosur inform page report
rational contessa studi design
contessa pivot trial intend confirm whether tesetaxel plu low-
dose capecitabin improv show manag toxic
oral regimen tesetaxel low-dos capecitabin oral
natur synergist mechan action taxan plu fluoropyrimidin
capecitabin serv appropri control capecitabin prefer
oral agent fluoropyrimidin chemo mbc patient
neg hr-posit statu repres appropri control regimen
approv dose capecitabin larg benefit patient previous
treat taxan neoadjuv prior surgeri adjuv immedi
follow surgeri advanc set
unmet need chemo combo kol emphas high unmet need
combin chemo regimen show improv benefit-risk profil
regimen docetaxel-capecitabin improv increas os
risk increas toxic
exampl capecitabin combin iv taxan gener toxic
combin capecitabin intraven taxan improv efficaci caus
howev low-dos capecitabin reduc toxic preserv efficaci
preclin clinic studi show low-dos cape taxan combin
reduc toxic without reduc efficaci exampl phase studi tesetaxel
low-dos capecitabin show toler ae profil minim
tesetaxel single-ag show activ tesetaxel monotherapi shown
antitumor activ two phase ii studi mbc first-lin chemo
overview prior tesetaxel studi
daiichi sankyo start develop tesetaxel variou
cancer daiichi ran phase ii studi patient
compani out-licens drug genta march exchang
undisclos up-front payment futur mileston royalti licens
agreement genta ran tesetaxel studi howev genta file
bankruptci august fda reject lead product genasens
in-licens right tesetaxel major market daiichi
concurr acquir right tesetaxel genta bankruptci estat
genta daiichi administ tesetaxel
patient across clinic studi includ monotherapi combin
studi metastat breast cancer mbc gastric cancer colorect cancer non-smal
cell lung cancer nsclc salvag set tesetaxel studi result
avail studi data collect remain studi still
underway trial interrupt abruptli due genta bankruptci
highlight clinic studi conduct daiichi genta
page
pleas see import disclosur inform page report
chart summari prior tesetaxel studi
page
pleas see import disclosur inform page report
studi statuspati populationregimentes dose mono iiresult mono iiresult combo w/ low-dos cape ibresult tumor colon breast bladder pancreat etc tese cape combo w/ cape iresult tumor pancreat liver colon breast etc tese cape vs cape mbc te vs iiresult mono iiresult flat flat combo w/ cape ci i/i tesegast gentaefficaci combo w/ low-dos cape gastrictes cape vs cape iiresult iiresult mono mono mono mono datasolid dlt pk mono icompletedsolid dlt pk mono iterminatedsolid toler dose datasolid /- food icompletedsolid
chart summari tesetaxel efficaci profil variou cancer across differ line therapi
page
pleas see import disclosur inform page report
studi populationtes ptsevaluableefficaci eval orrcr best pr best sd best pd tumor colon breast bladder pancreat tumor pancreat liver colon breast studi conduct prior sponsor studi includ patient receiv tesetaxel everi day cohort pt receiv weekli tesetaxel discontinu earli due studi termin
chart summari tesetaxel safeti toler profil across variou studi
page
pleas see import disclosur inform page report
studi iiiiibiiiiiiiiiipati mbcsolid tumorssolid nsclcsolid tumors/ lymphomaregimentesetaxeltesetaxeltesetaxel dose treat patient safeti cohort dose dose dose dose cohort dose dose dose total evalu hair loss grade white blood neutropenia fever platelet mean disclos assum zero low single-digit percentag
monotherapi data chemo mbc patient
show orr month
present genta phase ii studi
treat chemo nave mbc patient tesetaxel monotherapi
although studi includ patient previous chemo includ taxan
adjuv set last dose given month prior entri thirty-
one enrol patient previous anti-estrogen therapi
common hormon drug call tamoxifen patient
receiv prior chemo adjuv set patient receiv taxane-
contain regimen plan publish phase ii result offici
inclus criteria adult femal local advanc metastat breast
cancer er er- status measur diseas revis recist
version ecog perform statu
dose schema patient initi given oral antiemet prevent
vomiting/nausea took tesetaxel oral everi week
studi design allow escal subsequ cycl
depend patient toler tesetaxel
durat treatment continu month patient could
transit extens studi addit cycl
chart prior treatment baselin
patient evalu receiv least one tumor
scan one patient discontinu due diarrhea anoth discontinu due
escal dose group includ patient
cycl tesetaxel median administ
confirm orr pt base two tumor scan separ
least four week apart confirm orr includ cr pr
confirm stabl diseas sd seen patient confirm
progress diseas pd seen patient
unconfirm overal orr base singl scan unconfirm
orr includ cr pr
page
pleas see import disclosur inform page report
prior treatment characteristicstot characteristicsag median receptor statu metastatsi metastasi site
unconfirm overal orr non-escal cohort
pt escal cohort pt
orr patient within er subgroup
orr patient within tnbc subgroup
overal stabl diseas sd seen patient overal progress
diseas pd seen patient
median month patient month among patient
hr diseas specif er
chart confirm best respons studi
chart unconfirm overal respons rate orr patient subgroup
page
pleas see import disclosur inform page report
chart maximum tumor volum chang baselin monotherapi
studi tesetaxel non-escal dose group vs dose escal dose group
genta show maintain dose without escal
result superior toxic profil drug fewer grade occur
non-escal dose group notabl incid grade neutropenia
non-escal group versu escal group tesetaxel gener well
toler common grade advers event neutropenia
occur total patient
peripher neuropathi mild low incid grade occurr
febril neutropenia develop fever uncommon affect patient
expect hypersensit reaction grade
notabl instanc grade peripher neuropathi
non-escal cohort dose chosen phase
contessa trial grade neuropathi occur dose-escal cohort
incid grade alopecia hair loss across group
chart summari grade advers event
page
pleas see import disclosur inform page report
grade appetiteextrem painmuscular low platelet fatiguehypokalemia low potassium peripher neuropathygrad
tesetaxel monotherapi data
chemo show notabl activ taxane-resist
conduct daiichi sankyo studi
evalu mbc patient receiv initi dose
tesetaxel chemotherapi
patient receiv tesetaxel chemotherapi
patient prior chemo one prior chemo regimen
two prior chemo regimen
median age year median time diagnosi breast cancer
patient receiv anthracycline-bas regimen adjuv
common metastat site includ liver patient bone lymph
node lung
efficaci safeti result
dose group includ patient
patient complet least one cours therapi
consid evalu efficaci one patient discontinu due pulmonari
embol unrel tesetaxel anoth patient discontinu due diseas
confirm orr pt consist pr
stabl diseas sd occur patient diseas progress pd
occur
unconfirm orr pt
median time-to-progress month
common grade ae neutropenia pt incid grade
febril neutropenia
grade neuropathi grade alopecia
chart confirm best respons studi
page
pleas see import disclosur inform page report
efficaci mbc patient high vs p-gp express
daiichi conduct immunochemistri stain tumor biopsi
taxane-experienc patient break patient high low p-gp
express tumor high p-gp level gener suggest resist taxan
taxane-experienc patient consist nine p-gp high patient eight p-gp low
daiichi saw unconfirm orr p-gp high pt p-
gp low pt provid clinic evid tesetaxel retain cell-
kill cytotox potenc regardless p-gp express level
believ attribut differenti tesetaxel taxan
paclitaxel docetaxel shown lose cytotox potenc
tumor taxane-resist p-gp posit
chart unconfirm respons level p-gp express
page
pleas see import disclosur inform page report
grade neuropathyvomitinganorexiahypokalemiaselect grade patient low white blood cell anemia low red blood cell febril neutropenia respons rate sd stabl diseas pd progress diseas high p-gp expressionlow p-gp
tesetaxel low-dos capecitabin solid
phase safeti studi solid tumor genta
phase studi evalu tesetaxel-capecitabin low dose
patient advanc solid tumor provid earli evid
combin regimen achiev toler ae profil minim
overlap toxic approv capecitabin dose day
although patient sustain treatment dose level due hand-foot
inclus patient prior line chemotherapi prior
cycl patient receiv oral tesetaxel first day
plu either oral capecitabin daili
common grade neutropenia neutropenia
revers manag support measur
febril neutropenia occur high-dos capecitabin
grade neuropathi
grade hand-foot syndrom
grade diarrhea
expect grade alopecia hypersensit
importantli frequenc time first dose reduct
phase studi favor genentech phase pivot mbc studi
latter enabl genentech receiv regulatori approv capecitabin
xeloda compar docetaxel-capecitabin versu capecitabin alon
chart compar dose reduct tesetaxel low-dos capecitabin versu docetaxel approved-dos
phase studi solid tumor daiichi
studi evalu patient advanc metastat solid tumor
patient receiv prior surgic treatment receiv prior
system therapi median two regimen
page
pleas see import disclosur inform page report
